VRCDF (Verici Dx) Price-to-Tangible-Book : 0.77 (As of Jul. 19, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Price-to-Tangible-Book?

As of today (2025-07-19), Verici Dx's share price is $0.01. Verici Dx's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $0.01. Hence, Verici Dx's Price to Tangible Book Ratio of today is 0.77.

The historical rank and industry rank for Verici Dx's Price-to-Tangible-Book or its related term are showing as below:

VRCDF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1 Med: 6.22 Max: 13.93
Current: 1

During the past 5 years, Verici Dx's highest Price to Tangible Book Ratio was 13.93. The lowest was 1.00. And the median was 6.22.

VRCDF's Price-to-Tangible-Book is ranked better than
82.21% of 163 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.76 vs VRCDF: 1.00

A closely related ratio is called PB Ratio. As of today, Verici Dx's share price is $0.01. Verici Dx's Book Value per Sharefor the quarter that ended in Dec. 2024 was $0.02. Hence, Verici Dx's P/B Ratio of today is 0.45.

Verici Dx Price-to-Tangible-Book Historical Data

The historical data trend for Verici Dx's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Price-to-Tangible-Book Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

2.50

12.22

2.31

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial				2.50	5.96	12.22	2.81	2.31

Competitive Comparison of Verici Dx's Price-to-Tangible-Book

For the Diagnostics & Research subindustry, Verici Dx's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Price-to-Tangible-Book Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Verici Dx's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Verici Dx Price-to-Tangible-Book Calculation

Verici Dx's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	0.01	/	0.013
	=	0.77

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Verici Dx Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Verici Dx's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

VRCI:UK 63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines